Similarly, the group of DPP4-inhibitors had hardly any impact on glucose control when used in T1D and did not prove sufficient efficacy in preserving β-cell function in persons with new-onset diabetes. This evidence concerns the gene DPP4 and type 1 diabetes mellitus.